Bryan, Garnier & Co Healthcare Daily | Calliditas

Reports Q1 2023 results, sees sales uptake by the end of the quarter

Q1 2023 Tarpeyo sales reached SEK 186m (USD 17m), representing a modest 11% increase vs. the previous quarter. The ambitious FY 2023 net sales guidance for Tarpeyo of USD 120-150m was reiterated, as the company expects sales to further grow in the coming quarters considering that i) Q1 enrollment w

Onward: Model Update

We update our financial model after Onward medical released FY 2023 results last week The rating remains unchanged with a Buy recommendation and EUR 20 PT.

Hugo Boss: Weak China and month of April spoilt the mood

In our view, the sharp negative market reaction was triggered by subdued trends in China and April trends which were slightly below the Q1 top-line performance (+6% FX-n), on top of another tough comparison base (Q2 2023: +20% FX-n). Whilst FY24 outlook was reiterated, management's relatively cauti

Egetis reports Q1, on track with US trial

Egetis reported Q1 2024 results with an operating loss of SEK (68.6m) and a cash position of SEK 251.7m. In the pipeline, the most important update has been to the status of the critical US phase 3 trial, where the company reported that 13/16 patients have been recruited, whereof 6 patients have co